|
|
|
|
Glancy Binkow & Goldberg LLP, Representing Investors Who Purchased Cell Therapeutics, Inc., Announces Class Ac
- Notice is hereby given that Glancy Binkow & Goldberg LLP has filed a class action lawsuit in the United States District Court for the Western District of Washington on behalf of a class consisting of all persons or entities who purchased the...
|
|
|
Glancy Binkow & Goldberg LLP, Representing Investors Who Purchased Cell Therapeutics, Inc., Announces Class Ac
Notice is hereby given that Glancy Binkow & Goldberg LLP has filed a class action lawsuit in the United States District Court for the Western District of Washington on behalf of a class consisting of all persons or entities who purchased the...
|
|
|
Glancy Binkow & Goldberg LLP, Representing Investors Who Purchased Cell Therapeutics, Inc., Announces Class Action Lawsuit and Seeks to Recover Losses
LOS ANGELES-- (BUSINESS WIRE) -- Notice is hereby given that Glancy Binkow & Goldberg LLP has filed a class action lawsuit in the United States District Court for the Western District of Washington on behalf of a class consisting of all persons...
|
|
|
Glancy Binkow & Goldberg LLP, Representing Investors Who Purchased Cell Therapeutics, Inc., Announces Class Ac
Notice is hereby given that Glancy Binkow & Goldberg LLP has filed a class action lawsuit in the United States District Court for the Western District of Washington on behalf of a class consisting of all persons or entities who purchased the...
|
|
|
FDA: High-Dose Simvastatin Given With Certain Drugs Increases Risk of Myopathy
my personal edition> cholesterol/lipid disorders > news E-Mail this DGNews to a colleague DGNews ROCKVILLE, Md -- March 19, 2010 -- Based on review of data from a large clinical trial and data from other sources, the US Food and Drug...
|
|
|
Jury finds Seroquel didn't cause diabetes
TRENTON - AstraZeneca P.L.C.'s blockbuster psychiatric drug Seroquel did not trigger diabetes in a Vietnam veteran, a jury found yesterday in the first trial out of thousands of cases alleging the powerful drug caused diabetes.The British...
|
|
|
Glancy Binkow & Goldberg LLP, Representing Investors Who Purchased Cell Therapeutics, Inc., Announces Class Ac
A copy of the Complaint is available from the court or from Glancy Binkow & Goldberg LLP.Please contact us by phone to discuss this action or to obtain a copy of the Complaint at (310) 201-9150 or Toll Free at (888) 773-9224, by email at shareholders...
|
|
|
Scientists Honored With Discoverers Award for Development of Innovative HIV Medicine Maraviroc
10:46 AM EDT WASHINGTON, March 18 /PRNewswire-USNewswire/ -- Three scientists who led the 11-year quest to develop a groundbreaking HIV drug today received the 2010 Discoverers Award -- the highest honor given to scientists by the Pharmaceutical Research...
|
|
|
::: Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic Constipation
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals, Inc.(OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients...
|
|
|
Almost 62% of Canadians age 65 and older use five or more classes of prescription drugs: CIHI study
Drugs to treat cardiovascular conditions top the list in both use and cost for public drug programs Almost two-thirds (62%) of Canadians age 65 and older living in the community in six provinces are using five or more classes of prescription ...
|
|
|
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
Author : Dow Jones & Company Category : Press Release News Alerts by Email ( click here ) News | Home NEW YORK, March 19 -- After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of...
|
|
|
UPDATE: FDA panel green-lights BSX on expanded CRT-D indication
Boston Scientific Corp.wins an important decision before a Food & Drug Administration panel, which granted its application to extend the indication for its implantable defibrillators to cover milder forms of heart failure. If the FDA clears the...
|
|
|
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
NEW YORK, March 19 /PRNewswire/ -- After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires reported that it will be difficult to convince prescribers to...
|
|
|
The Drugs Are Working For Roche
Roches investor day left little doubt about the Swiss pharmaceutical giants conviction that its experimental drug pipeline will keep it on the path of success.The firm touted that about ten experimental medicines could reach annual sales of more than 2...
|
|
|
Somaxon Stock Wakes Up On FDA Approval Of Sleep Drug - Update
(RTTNews) - Persistence has paid off for development-stage biotech company Somaxon Pharmaceuticals Inc.(SOMX). The company's insomnia drug candidate Silenor, which has been thrice at the FDA altar, finally won the regulatory approval Thursday,...
|
|
|
Somaxon Stock Wakes Up On FDA Approval Of Sleep Drug - Update
(RTTNews) - Persistence has paid off for development-stage biotech company Somaxon Pharmaceuticals Inc.(SOMX). The company's insomnia drug candidate Silenor, which has been thrice at the FDA altar, finally won the regulatory approval Thursday,...
|
|
|
FDA green-lights BSX on expanded CRT-D indication
Boston Scientific Corp.wins an important decision before a Food & Drug Administration panel, which granted its application to extend the indication for its implantable defibrillators to cover milder forms of heart failure. A Food & ...
|
|
|
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
See more news releases in: Publishing & Information Services, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Surveys, Polls and Research NEW YORK, March 19 /PRNewswire/ -- After Canadian specialty pharmaceutical company...
|
|
|
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
NEW YORK, March 19 /PRNewswire/ -- After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires reported that it will be difficult to convince prescribers to...
|
|
|
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
NEW YORK, March 19 /PRNewswire/ -- After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires reported that it will be difficult to convince prescribers to...
|
|
|
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
NEW YORK, March 19 /PRNewswire/ -- After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires reported that it will be difficult to convince prescribers to...
|
|
|
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
NEW YORK, March 19 /PRNewswire/ -- After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires reported that it will be difficult to convince prescribers to...
|
|
|
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
Companies mentioned in this article: Dow Jones & Company NEW YORK, March 19 /PRNewswire/ -- After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires...
|
|
|
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
NEW YORK, March 19 /PRNewswire/ -- After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires reported that it will be difficult to convince prescribers to...
|
|
|
Three scientists receive 2010 Discoverers Award for developing new class of HIV drug
Three scientists who led the 11-year quest to develop a groundbreaking HIV drug today received the 2010 Discoverers Award -- the highest honor given to scientists by the Pharmaceutical Research and Manufacturers of America (PhRMA).The honorees are Tony...
|
